# Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine

> **NCT00800956** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 4 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** [14C]-esreboxetine

## Key facts

- **NCT ID:** NCT00800956
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 4 (ESTIMATED)
- **Last updated:** 2011-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00800956

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00800956, "Phase I Study to Determine the Absorption, Distribution, Metabolism and Excretion of Esreboxetine". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT00800956. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*